Breaking News Instant updates and real-time market news.

UNH

UnitedHealth

$134.24

0.32 (0.24%)

14:47
10/17/16
10/17
14:47
10/17/16
14:47

UnitedHealth technical notes before earnings news, topping process underway

The shares have been in a shallow downtrend since late September of this year. On a 1-year daily chart, closing price basis, this downtrend is part of a larger topping process that is underway. A move below $130 on negative news would void support going back to May of this year. Additional support levels to watch in that event as potential downside objectives would be at $128.53 and then at $125.26. If the news is a positive surprise, a move above the $137 area would break the downtrend resistance line. Next resistance would then be at $140.51, $142.85, and the 52-week high at $144.48.

  • 18

    Oct

UNH UnitedHealth
$134.24

0.32 (0.24%)

09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
09/22/16
PIPR
09/22/16
NO CHANGE
Target $155
PIPR
Overweight
UnitedHealth won VA contract worth $1B per year, says Piper Jaffray
Piper Jaffray analyst Sean Wieland says UnitedHealth unit Optum has won a contract with the U.S. Department of Veterans Affairs to provide medical disability examinations. The analyst estimates the contract, awarded to Optum wholly owned subsidiaries Logistics Health and Medical Support Los Angeles, represents $1B per year. Wieland estimates the award will be neutral to earnings in year one and become accretive in 2018. He reiterates an Overweight rating on UnitedHealth shares with a $155 price target.
09/22/16
EVER
09/22/16
INITIATION
Target $155
EVER
Buy
UnitedHealth initiated with a Buy at Evercore ISI
Evercore ISI initiated UnitedHealth with a Buy and a $155 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.